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Novel CDKN2A Mutations Detected in Western
Swedish Families with Hereditary Malignant
Melanoma
Anna Erlandson1, Frida Appelqvist2, Ann-Marie Wennberg2, Joanna Holm2 and Charlotta Enerba¨ck1,2
We have examined alterations in the cyclin-dependent kinase inhibitor 2A (CDKN2A), a major melanoma
predisposing gene, in a western-Swedish hereditary melanoma population comprising 107 patients from 68
families. Using sequence analysis and multiplex ligation-dependent probe amplification, we found a novel
mutation (Asp108 Tyr), segregating with the disease in three families. This mutation has previously been
detected as a somatic mutation in other cancers. We found a previously described Swedish founder mutation
(ins113Arg) in one family and a large duplication encompassing the CDKN2A gene locus in another family.
Moreover, a debated polymorphism (Ala148Thr) was found in nine families, in which the polymorphism did not
segregate with the disease.
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INTRODUCTION
The incidence of melanoma is high and rapidly increasing.
In Sweden, with a population of about nine million,
more than 1900 new cases of cutaneous melanoma were
diagnosed in 2004. As approximately 10% of cutaneous
melanomas are found in individuals with a hereditary
predisposition for the condition, 100–200 new cases can be
expected every year in members of these families, unless
successful preventive measures are taken. The search for
genetic markers of disease risk is therefore of continuing
medical interest.
Hereditary cyclin-dependent kinase inhibitor 2A
(CDKN2A) mutations have been demonstrated in the range
of 25–40% in different populations. A specific CDKN2A
mutation, an insertion of an extra arginine in codon 113 in
exon 2 (ins113Arg), dominates in the Swedish melanoma
families analyzed thus far (Borg et al., 1996).
We have surveyed the mutation spectrum in CDKN2A in
patients from western Sweden with hereditary malignant
melanoma. The reason for this is that the phenotype in this
region may be different from that in the rest of Sweden. First,
there is a higher incidence of malignant melanoma in western
Sweden compared with other parts of the country (The
Swedish Cancer Registry). Second, the population in western
Sweden exhibits an unusually high incidence of dysplastic
nevi (DN), which are risk factors or even precursors of
malignant melanoma. The prevalence of DN has been
reported to be as high as 18% (clinical diagnosis) and 8%
(histological diagnosis) (Augustsson et al., 1991). In addition,
previous studies have revealed genetic variations specific to
the region, including founder mutations (Enlund et al., 1999;
Bergman et al., 2001).
RESULTS AND DISCUSSION
Phenotypic characteristics
The study was performed on families with hereditary
melanoma followed up at the Departments of Dermatology
in the cities of Go¨teborg and Uddevalla on the Swedish west
coast. Table 1 summarizes the clinical characteristics for the
68 families participating in the study. The frequency of DN in
these families is high, as in the population as a whole. Among
the patients with melanoma in the study population, 53/60
also have DN (88.3%), which is a very high number
compared to other populations. Sixty-five of the kindred
have at least two first-degree relatives with melanoma, 32 at
least two second-degree relatives with melanoma, and 10 of
the kindred have more distant relatives with melanoma. The
diagnosis was confirmed by histopathology.
Previously described Swedish founder mutation
The previously described c.337_338insGTC mutation,
which leads to an in-frame insertion p.ins113Arg, was found
in one patient (Table 2). Interestingly, the high frequency of
DN in the population on the Swedish west coast was not
explained by an increased incidence in this founder
mutation.
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Novel mutation
In three of the families (seven patients), we found a novel
mutation that has not previously been reported in melanoma
patients. The mutation in p16 c.322G4T; Asp108Tyr (p14
Arg163Leu) was found in the heterozygous state (Figure 1).
This missense mutation affects a residue that is strictly
conserved among species (Mus musculus, Rattus norvegicus,
Canis familiaris, and Pan troglodytes; ENSG00000147889 in
Ensembl Genome Browser http://www.ensembl.org), which
supports the notion that a mutation at this site is detrimental
to the function of the protein. The presence among affected
relatives supports the probability of Asp108Tyr as a mutation
involved in the pathogenesis of malignant melanoma.
The family pedigrees are outlined in Figure 2. There was
no indication of discordant individuals in these families; the
mutation therefore showed linkage to the disease. Cosegrega-
tion of the novel mutation is suggested by our data, but would
require the testing of more affected and unaffected family
members for confirmation. In contrast, this mutation was not
detected in 84 chromosomes from healthy blood donors
living in this region.
The shift involves aspartic acid (Asp), an acidic-charged
polar hydrophilic amino acid, which has a relatively small
side chain in comparison to the amino acid tyrosine (Tyr),
which is an uncharged polar hydrophobic amino acid with a
phenol structure in the side chain. Both the steric differences
and the shift from a hydrophilic to a hydrophobic amino acid
suggest a functional significance. Although Asp108Tyr has
not previously been described in malignant melanoma, the
same amino acid shift has been reported in several other
tumors. However, in contrast to these studies, this is the first
study showing this disease-causing mutation in the germ line.
Interestingly, another amino acid shift, Asp108Asn, which
affects the same amino-acid position, has been described in
malignant melanoma families (Flores et al., 1997). This shift
was shown functionally to impair the protein, resulting in
reduced affinity to Cdks compared with that of the wild type
(Huot et al., 2002).
Normal variants
In this study, nine of the families had a variant of CDKN2A:
c.442G4A; Ala148Thr (Table 2). It has been described as a
normal variant in the UK population (Bertram et al., 2002),
but this variant has been shown to predispose to malignant
melanoma in Poland (Debniak et al., 2005). We detected this
variant in 10 patients, which corresponds to a frequency of
9.3% in this patient sample. It was present in two of three
family members with malignant melanoma in one family,
which is in line with previous suggestions that this variant
represents a normal polymorphism. However, its importance
as a low-penetrant disease allele is still to be determined.
We detected a mutation in one family, c.318G4A, silent
in p16 (Val106Val), but causing an amino-acid shift in p14
(Ala162Thr; Table 2 ). It is likely to represent a normal variant
T G C G G/T A
Asp/Tyr
T G C CC
Figure 1. The c.322G4T; Asp108Tyr mutation detected in three families.
Sequence analysis of polymerase chain reaction-amplified genomic DNA
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Figure 2. Pedigrees of melanoma families with the mutation Asp108Tyr.
In three of the families (a total of seven patients), we found a novel mutation.
*Indicates tested individuals, all positive for the CDKN2A mutation.
Table 1. Number of primary melanomas and number
of affected relatives
Number of primary
melanomas per individual
Total number
of families
1 48 (71%)
2 141 (21%)
3 5 (7%)
4 1 (1%)
Number of affected relatives with
malignant melanomas
Total number
of families
2 47 (69%)
3 18 (26.5%)
4 1 (1.5%)
6 1 (1.5%)
7 1 (1.5%)
111 families with 1 affected individual with 2 malignant melanomas, and
3 families with 2 affected individuals with 2 malignant melanomas each.
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as it has been reported in a family where it was not present in
all family members with the disease and therefore did not
show linkage with the disease (FitzGerald et al., 1996).
Deletion screening using MLPA
In order to improve the sensitivity of the genetic screening,
we used MLPA (multiplex ligation-dependent probe amplifi-
cation), which identifies deletions and duplications encom-
passing the CDKN2 locus. One patient displayed the
duplication of all exons of CDKN2A and CDKN2B (Figure 3).
In this family, two patients have had melanoma, but neither
of them was available for genetic analysis. Even if this implies
a very large rearrangement of the CDKN2A/CDKN2B loci,
the clinical significance of this variant is not evident.
A recent study found deletions using MPLA in three of the
93 UK families (Mistry et al., 2005). Our finding supports the
conclusion that duplications and deletions in CDKN2 in
hereditary melanoma as assessed by MLPA are rare, but
possibly, clinically significant events. Interestingly, this is the
first report of a duplication of CDKN2A and 2B.
The low frequency of mutations in CDKN2A in a cohort
with an unusually high frequency of DN strongly suggests
that other, as yet unknown, genes are operative in the
development of DNS.
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Figure 3. Duplication of CDKN2A and CDKN2B. The MLPA analysis
detected in one patient with duplication of all 12 probes located in CDKN2A
and 2B. The probe-lengths correspond to the MLPA kit P024 (MRC). Specific
probes are assigned for the genes CDKN2A and 2B. Probe-lengths for
CDKN2A are 148, 157, 238, 256, 265, 274, 355, 391, 427 bp and 454 bp for
CDKN2B 202, 211. The additional probes in the figure are located in the
surrounding genes at 9p21. Upper panel shows blue bars from normal control
and green bars from a patient with melanoma. Lower panel shows the results
as dosage of patient compared to control; two alleles are 100% and three
alleles are 150% (the red line indicates cutoff at 720%). Sequence pilot
version 1.2 software (JSI medical systems) was used for quantification analyses.
Table 2. Mutations and normal variants in CDKN2A detected by sequencing
Effect on p16 Effect on p14
Nucleotide change p16 Aminoacid shift p16 Nucleotide change p14 Aminoacid shift p14 Type of mutation Number of families
c.337_139dupGTC p.ins113A1 c.502_504dupGTC p.Ser168dup Insertion 1
c.318G4A p.Val106Val c.484G4A p.Ala162Thr Substitution2 1
c.322G4T p.Asp108Tyr c.488G4T p.Arg163Leu Substitution 3
c.442G4A p.Ala148Thr c.522+86G4A — Substitution3 9
1p.Arg113dup.
2Silent mutation p16.
3Substitution in p16, located in p14 30-UTR.
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